Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-9-4
pubmed:abstractText
Some rectal cancers respond well to preoperative neoadjuvant therapy while others are inherently resistant or develop resistance during the treatment. To understand the mechanism underlying these differences, several markers that might be prognostic or predictive of downstaging in response to chemoradiotherapy in patients with rectal cancer were evaluated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0167-8140
pubmed:author
pubmed:issnType
Print
pubmed:volume
80
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
172-7
pubmed:meshHeading
pubmed-meshheading:16905208-Adult, pubmed-meshheading:16905208-Aged, pubmed-meshheading:16905208-Cyclooxygenase 2, pubmed-meshheading:16905208-Female, pubmed-meshheading:16905208-Fluorouracil, pubmed-meshheading:16905208-Humans, pubmed-meshheading:16905208-Immunohistochemistry, pubmed-meshheading:16905208-Interleukin-6, pubmed-meshheading:16905208-Ki-67 Antigen, pubmed-meshheading:16905208-Male, pubmed-meshheading:16905208-Membrane Proteins, pubmed-meshheading:16905208-Middle Aged, pubmed-meshheading:16905208-Neoadjuvant Therapy, pubmed-meshheading:16905208-Osteopontin, pubmed-meshheading:16905208-Preoperative Care, pubmed-meshheading:16905208-Prognosis, pubmed-meshheading:16905208-Pyrazoles, pubmed-meshheading:16905208-Rectal Neoplasms, pubmed-meshheading:16905208-Sulfonamides, pubmed-meshheading:16905208-Tumor Markers, Biological
pubmed:year
2006
pubmed:articleTitle
Molecular responses of rectal cancer to preoperative chemoradiation.
pubmed:affiliation
Department of Radiation Oncology and Experimental Radiation, Leuven Cancer Institute, University Hospital Leuven, Belgium. annelies.debucquoy@med.kuleuven.be <annelies.debucquoy@med.kuleuven.be>
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II